Philippe Wolgen - Realord Group CEO

Dr. Philippe J. Wolgen, MBA, M.D., is Chief Executive Officer, Managing Director, Executive Director of Clinuvel Pharmaceuticals Ltd. Dr Wolgen was appointed as Managing Director of CLINUVEL in November 2005 to lead the corporate turnaround of the Group. Under his leadership a longterm strategy for CLINUVEL was devised and the lead product SCENESSE reformulated, its medical application identified, and European marketing authorisation ultimately obtained. SCENESSE is the first melanocortin drug to have completed a clinical trial program and obtain marketing authorisation in a major market. Dr Wolgen was instrumental in rebuilding a share register of longterm sophisticated and institutional investors. His international contacts and network contribute to the strategic support CLINUVEL enjoys globally. He led CLINUVEL to attract more than AUD95 million in direct funding to develop and launch SCENESSE and succeeded in guiding the Group through a complex pharmaceutical development program. Dr Wolgen is now leading the Groups expansion, with an immediate focus on the US and the further development of the Groups product pipeline in various market segments. His focus was to establish a professional management team to execute the corporate objectives set and to prepare the next generation of managers. Dr Wolgens long track record shows a strongly focussed, competitive and ethical professional who perseveres in meeting business objectives. He holds an MBA from Columbia University NY and the London Business School. Trained as a craniofacial surgeon, Dr Wolgen obtained his MD from the University of Utrecht, the Netherlands. since 2005.